Acticor News Today

ACTICOR BIOTECH: Report of the Combined General Meeting of May 12, 2023

May 17, 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular

Newton Biocapital Gewinn Nur French National Institute Of Health Venture Investment European Medicines Agency Regulatory News

Source: finanznachrichten.de

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2023

May 9, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including

Newton Biocapital Regulation Of The French Financial Markets Authority French National Institute Of Health Venture Investment European Medicines Agency Regulatory News

Source: finanznachrichten.de

Acticor Biotech: Disclosure of The Total Number of Voting Rights and Shares as of March 31, 2023

April 11, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

France General Newton Biocapital European Medicines Agency French National Institute Of Health Regulation Of The French Financial Markets Authority Venture Investment

Source: finanznachrichten.de

Acticor Biotech Publishes Its 2022 Annual Results and Provides an Update on Its Clinical Progress

March 23, 2023

Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients

United Kingdom France General United States Czech Republic Great Britain Newton Biocapital

Source: finanznachrichten.de

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of February 28, 2023

March 3, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

France General Dennis Riedl Newton Biocapital Venture Investment French National Institute Of Health Regulation Of The French Financial Markets Authority

Source: finanznachrichten.de

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023

February 8, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

France General Newton Biocapital Schwierige Zeiten Venture Investment French National Institute Of Health Regulation Of The French Financial Markets Authority

Source: finanznachrichten.de

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

January 6, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

France General Newton Biocapital Kepler Cheuvreux Venture Investment French National Institute Of Health European Medicines Agency

Source: finanznachrichten.de

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2022

January 6, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

France General Newton Biocapital Venture Investment French National Institute Of Health Regulation Of The French Financial Markets Authority European Medicines Agency

Source: finanznachrichten.de

Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA

December 23, 2022

Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular

United States France General Newton Biocapital Gilles Avenard Venture Investment French National Institute Of Health

Source: finanznachrichten.de

Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023

December 1, 2022

Regulatory News: Acticor Biotech (Euronext Growth Paris ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company, a spin-off of INSERM, developing an innovative drug for

France General Newton Biocapital Venture Investment French National Institute Of Health European Medicines Agency Regulatory News

Source: finanznachrichten.de

Navigation

Acticor News Today

ACTICOR BIOTECH: Report of the Combined General Meeting of May 12, 2023

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2023

Acticor Biotech: Disclosure of The Total Number of Voting Rights and Shares as of March 31, 2023

Acticor Biotech Publishes Its 2022 Annual Results and Provides an Update on Its Clinical Progress

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of February 28, 2023

Stay Updated with Latest News

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2022

Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA

Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023

Explore More Categories